Why the study?
Visceral adipocyte secretory molecules influence cardiovascular pathophysiology, and adipokines may serve as diagnostic, prognostic, or therapeutic targets in abdominal obesity-associated cardiovascular disease.
Key points are not available for this paper at this time.
Design
Review
Supports adipokine biomarker research in abdominal obesity-related CVD; hypothesis-generating and should not yet alter practice.
Adipose tissue is considered one of the endocrine organs in the body because of its ability to synthesize and release a large number of hormones, cytokines, and growth and vasoactive factors that influence a variety of physiological and pathophysiological processes, such as vascular tone, inflammation, vascular smooth muscle cell migration, endothelial function, and vascular redox state. Moreover, genetic factors substantially contribute to the risk of obesity. Research into the biochemical effects of molecules secreted by visceral adipocytes as well as their molecular genetic characteristics is actively conducted around the world mostly in relation to pathologies of the cardiovascular system, metabolic syndrome, and diabetes mellitus. Adipokines could be developed into biomarkers for diagnosis, prognosis, and therapeutic targets in different diseases. This review describes the relevance of secretory activity molecules of visceral adipocytes in cardiovascular disease associated abdominal obesity.
No takes yet. Share an insight, caveat, or question.
Ragino et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: